January 2013 – News from the OACPosted in: Educational Resources
This Post has 1 Comment
OAC Welcomes New Director to our National Board of Directors
The OAC is proud to welcome Michelle Vicari to our National Board of Directors! Michelle is a self-employed freelance writer from Temecula, CA., and a long-time member of the OAC and currently serves on the OAC Membership Committee.
Michelle is well-known for her Blog, The World According to Eggface, which is designed to support individuals in their life-long journey with obesity. She is a strong advocate for the OAC, having participated in the OAC’s Day on the Hill in Washington, DC, last year and was recently the recipient of the 2012 Outstanding Membership Recruitment by an OAC Member award. Michelle is a gastric bypass patient, having successfully maintained a 158-pound weight-loss for nearly seven years.
The OAC would also like to congratulate several of our Directors on their re-election to the Board: Pam Davis, RN, CBN, BSN; Jim Fivecoat, MBA; Ted Kyle, RPh, MBA; Walter Lindstrom, Esq.; Georgeann Mallory, RD; Tracey Martinez, RN, BSN, CBN and Lloyd Stegemann, MD, FASMBS. The OAC is grateful for all of their hard work and dedication to our organization!
For more information on the OAC’s National Board of Directors, please click here.>>>
Obesity Medications – Where are We Now?
Throughout the past few months, the OAC has received a high volume of questions regarding the new obesity medications (Qsymia® and Belviq®). In an effort to answer questions, the OAC published an article, titled “Obesity Medications – Where are We Now?” in the fall issue of Your Weight Matters Magazine.
This article takes a close look at all current obesity medications, who qualifies for them, average weight lost and much more. “The accessibility of these obesity medications greatly increases the amount of treatment options available to individuals battling excess weight or obesity, and wanting to improve their health. Recently, Express Scripts and other health insurance providers have indicated availability of obesity medications in their plans and formularies. This is an excellent step in the right direction,” said Joe Nadglowski, OAC President and CEO. For more information on health insurance coverage of obesity medications, please contact your insurance provider. The OAC has compiled a list of insurance providers to help you easily access them. To view the list, click here.
“Obesity Medications – Where are We Now?” is an excellent resource for both individuals affected by excess weight and obesity, and healthcare providers. If you have questions regarding the new obesity medications and would like to learn more, please click here.
UPDATE on Qsymia®
Since the printing of the article, Vivus, Inc., manufacturer of Qsymia®, has announced that Express Scripts, one of the nation’s largest Pharmacy Benefit Managers, has added Qsymia® to its National pharmacy formularies, allowing for coverage where available by benefit design. Under the Express Scripts plan, participating patients will now pay an estimated $50-$60 (approximately one-third of the retail price) for their co-payment for a monthly prescription of Qsymia®.
Vivus also launched a brand new program, titled the “Get Started! Program.” For a limited time through this program, patients with a written prescription for Qsymia® can receive their first two weeks of treatment for free. *Please Note: Your doctor must fax the prescription for you to one of the participating home delivery pharmacies (CVS Pharmacy, Walgreens, Express Scripts or Wal-Mart Home Delivery Pharmacy).For more information on this program, click here.
UPDATE on Belviq®
Belviq® has now received its proposed DEA Scheduling, which is the next step in availability of this medication. At this time, Belviq® is estimated to be available through prescription within the first half of this year. For more information on Belviq®, please click here.